Study Finds Continuing Vs Discontinuing Antifungal Prophylaxis After Allogeneic HCT Does Not Affect IMI Incidence, NRM, Or Overall Survival

Infectious Disease Advisor (8/27, Kuhns) reports, “Continuing vs discontinuing antifungal prophylaxis after allogeneic hematopoietic cell transplantation (HCT) does not significantly affect invasive mold infection (IMI) incidence, nonrelapse mortality (NRM), or overall survival, according to study results.” The researchers said, “Invasive mold infection after allo[geneic] HCT hospital discharge at day +100 was rare despite early discontinuation of antifungal prophylaxis, supporting a risk-adapted approach rather than universal prophylaxis and polypharmacy.” The findings were published in Open Forum Infectious Diseases.